64. (New) The immunogenic composition according to claim 61, wherein the immunostimulant induces a predominantly Th1-type response.

65. (New) A method for inducing an immune response in a patient, comprising administering to the patient the composition of any one of claims 61-64.

66. (New) An immunogenic composition comprising an immunostimulant and a polypeptide selected from the group consisting of:

(i) a polypeptide comprising the amino acid sequence provided in SEQ ID NO:176, or a portion thereof;

(ii) a polypeptide comprising an amino acid sequence having at least 75% identity to the sequence provided in SEQ ID NO:176, or a portion thereof; and

(iii) a polypeptide comprising an amino acid sequence having at least 90% identity to the sequence provided in SEQ ID NO:176, or a portion thereof;

wherein said polypeptide contains an amino acid sequence that is capable of stimulating T cells that are specific for an amino acid sequence present in the polypeptide set forth in SEQ ID NO:176.

67. (New) The immunogenic composition according to claim 66, wherein the immunostimulant is an adjuvant.

68. (New) The immunogenic composition according to claim 67, wherein the adjuvant comprises an adjuvant selected from the group consisting of a monophosphoryl lipid A, an aluminum salt, QS21, Montanide ISA 720, SAF, ISCOMS, MF-59, SBAS-2, SBAS-4, Detox, RC-529, and an aminoalkyl glucosaminide 4-phosphate.

69. (New) The immunogenic composition according to claim 66, wherein the immunostimulant induces a predominantly Th1-type response.